...
首页> 外文期刊>International Journal of Trichology >Unusual Pattern of Whitening of Eyebrows Following Sunitinib Therapy: A Case Report with Brief Review of Literature
【24h】

Unusual Pattern of Whitening of Eyebrows Following Sunitinib Therapy: A Case Report with Brief Review of Literature

机译:舒尼替尼治疗后眉毛增白的异常模式:病例报告并文献复习

获取原文
           

摘要

Sunitinib is a vascular endothelial growth factor receptor inhibitor which has shown high activity in metastatic renal cell carcinoma (mRCC) patients and is now widely used for the same. It is generally well tolerated, but sometimes, it exhibits a distinct pattern of novel side effects that require monitoring and management. Important known side effect of sunitinib includes fatigue, diarrhea, anorexia, skin toxicity, and hypertension which need special mention. Considering its effectiveness in first-line setting in mRCC and paucity of other good options, utmost efforts are made to continue it with identification of side effects which may require only slight dose modification or no dose alteration. We report here a 38-year-old male who was diagnosed as a case of mRCC and started on sunitinib at the diagnosis and developed whitish discoloration of eyebrows and body hairs after 3 months of starting sunitinib. In view of good overall response to treatment and no other significant toxicity, sunitinib was continued with good tolerability. Key words: Metastatic renal cell carcinoma, sunitinib, vascular endothelial growth factor
机译:舒尼替尼是一种血管内皮生长因子受体抑制剂,在转移性肾细胞癌(mRCC)患者中已显示出高活性,目前已被广泛使用。它通常具有良好的耐受性,但有时表现出独特的新型副作用模式,需要进行监控和管理。舒尼替尼的重要已知副作用包括疲劳,腹泻,厌食,皮肤毒性和高血压,需要特别提及。考虑到它在mRCC一线治疗中的有效性以及其他好的选择的不足,我们将尽最大努力继续进行它的鉴定,以确认可能仅需要微调剂量或不改变剂量的副作用。我们在这里报告了一名38岁的男性,他被诊断为mRCC病例,在诊断时开始使用舒尼替尼,并且在开始使用舒尼替尼3个月后出现了眉毛和体毛发白变色。鉴于对治疗的总体反应良好且无其他明显毒性,因此继续进行舒尼替尼且具有良好的耐受性。关键词:转移性肾细胞癌,舒尼替尼,血管内皮生长因子

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号